Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 3;14(6):1331-1341.
doi: 10.1080/21645515.2018.1438792. Epub 2018 Feb 26.

Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population

Stefano Capri  1 , Marco Barbieri  2 , Chiara de Waure  3 , Sara Boccalini  4 , Donatella Panatto  5   6
Affiliations

Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population

Stefano Capri et al. Hum Vaccin Immunother. .

Abstract

ABSRACT In the perspective of reaching at least 75% influenza vaccination coverage in the elderly and substantial budget constraints, Italian decision makers are facing important challenges in determining an optimal immunization strategy for this growing and particularly vulnerable population. Four different influenza vaccines are currently available for Italian older adults aged 65 years or above, namely trivalent inactivated vaccines (TIVs), MF59-adjuvanted TIV (MF59-TIV), intradermal TIV (ID-TIV) and quadrivalent inactivated vaccines (QIVs). The present study is the first to compare the cost-effectiveness profiles of virtually all possible public health strategies, including the aforementioned four vaccine formulations as well non-vaccination. For this purpose, a decision tree model was built ex novo; the analysis was conducted from the third-payer perspective in the timeframe of one year. All available vaccines were cost-effective compared with non-vaccination. However, MF59-TIV had the most favorable economic profile in the Italian elderly population. Indeed, compared with non-vaccination, it was deemed highly cost-effective with an incremental cost-effectiveness ratio (ICER) of €10,750 per quality-adjusted life year (QALY). The ICER was much lower (€4,527/QALY) when MF59-TIV was directly compared with TIV. ID-TIV and QIV were dominated by MF59-TIV as the former comparators were associated with greater total costs and lower health benefits. Both deterministic and probabilistic sensitivity analyses confirmed robustness of the base case results. From the economic perspective, MF59-TIV should be considered as a preferential choice for Italian older adults aged 65 years or above.

Keywords: Influenza; Italy; adjuvanted influenza vaccine; cost-effectiveness; costs; economic evaluation; elderly; vaccine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cost-effectiveness acceptability curves of all five study strategies.
Figure 2.
Figure 2.
Cost-effectiveness plane of the probabilistic sensitivity analysis (10,000 rounds): MF59-adjuvanted trivalent inactivated vaccine (MF59-TIV) versus trivalent inactivated vaccine (TIV).
Figure 3.
Figure 3.
Cost-effectiveness plane of the probabilistic sensitivity analysis (10,000 rounds): MF59-adjuvanted trivalent inactivated vaccine (MF59-TIV) versus no vaccination.
Figure 4.
Figure 4.
Simplified version of the decision tree.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007;7:658—66. doi:10.1016/S1473-3099(07)70236-0. PMID:17897608. - DOI - PubMed
    1. Monto AS, Ansaldi F, Aspinall R, McElhaney JE, Montaño LF, Nichol KL, Puig-Barberà J, Schmitt J, Stephenson I. Influenza control in the 21st century: optimizing protection of older adults. Vaccine. 2009;27:5043–53. doi:10.1016/j.vaccine.2009.06.032. PMID:19559118. - DOI - PubMed
    1. Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA, Jernigan DB, Bresee JS. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices – United States, 2016–17 influenza season. MMWR Recomm Rep. 2016;65:1–54. doi:10.15585/mmwr.rr6505a1. PMID:27560619. - DOI - PubMed
    1. European Centre for Disease Prevention and Control Seasonal influenza vaccination and antiviral use in Europe – Overview of vaccination recommendations and coverage rates in the EU Member States for the 2013–14 and 2014–15 influenza seasons. Stockholm: ECDC. 2016. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publicat... (Accessed 12October2017) 2016.
    1. Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec. 2012;87:461–76. PMID:23210147. - PubMed

Publication types

Substances

LinkOut - more resources